View : 40 Download: 0

Novel diether compounds inhibiting differentiation of osteoclasts

Title
Novel diether compounds inhibiting differentiation of osteoclasts
Authors
Doh K.E.Kang J.-H.Ting Z.Yim M.Choo H.-Y.P.
Ewha Authors
박혜영
SCOPUS Author ID
박혜영scopus
Issue Date
2016
Journal Title
Archives of Pharmacal Research
ISSN
0253-6269JCR Link
Citation
vol. 39, no. 2, pp. 178 - 190
Keywords
DifferentiationOsteoclastOsteoporosisRANKL
Publisher
Pharmaceutical Society of Korea
Indexed
SCIE; SCOPUS; KCI WOS scopus
Abstract
Osteoporosis is a disorder in which bone mass decreases and is responsible for many degenerative bone diseases. The excessive formation and activity of osteoclasts results in pathological disorders of the bone. Receptor Activator of Nuclear Factor κB Ligand (RANKL) is regarded as a key regulator of osteoclast activity and as a new therapeutic target for treating osteoporosis. Herein, we have synthesized several new small molecules and tested their inhibition activity on RANKL-induced osteoclast formation. The active compounds 2c and 4d showed inhibitory activity against RANKL-induced osteoclast differentiation (IC50 = 1.56 and 2.20 μM, respectively). The most active compound 2c prevented LPS-induced osteoclastogenesis in vivo. These data imply that the compound may be the potential candidate for a new therapeutic drug for treatment of bone resorption-associated diseases. © 2015 The Pharmaceutical Society of Korea.
DOI
10.1007/s12272-015-0672-x
Appears in Collections:
약학대학 > 약학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE